Thermo Fisher Scientific terminates Qiagen acquisition
Planned $11.5 billion acquisition of QIAGEN by Thermo Fisher Scientific is terminated, as only 47.02% of Qiagen shares were tendered. The deal was largest in medtech this year, until Siemens Healthineers announcement to acquire radiation oncology Varian Medical Systems for $16.4 Bn.
